Nektar Therapeutics Ownership
| NKTR Stock | USD 0.87 0.02 2.35% |
Shares in Circulation | First Issued 1994-03-31 | Previous Quarter 208.8 M | Current Value 209.2 M | Avarage Shares Outstanding 101.7 M | Quarterly Volatility 57.4 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Nektar |
Nektar Stock Ownership Analysis
About 73.0% of the company shares are owned by institutional investors. The book value of Nektar Therapeutics was now reported as 0.27. The company recorded a loss per share of 0.84. Nektar Therapeutics had not issued any dividends in recent years. The entity had 2:1 split on the 23rd of August 2000. Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California. Nektar Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 740 people. To find out more about Nektar Therapeutics contact Howard Robin at 415 482 5300 or learn more at https://www.nektar.com.Besides selling stocks to institutional investors, Nektar Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Nektar Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Nektar Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Nektar Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Only 1.27% of Nektar Therapeutics are currently held by insiders. Unlike Nektar Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Nektar Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Nektar Therapeutics' insider trades
Nektar Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Nektar Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Nektar Therapeutics backward and forwards among themselves. Nektar Therapeutics' institutional investor refers to the entity that pools money to purchase Nektar Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Renaissance Technologies Corp | 2024-12-31 | 3.9 M | State Street Corp | 2024-12-31 | 3.3 M | Altium Capital Management, Lp | 2024-12-31 | 3 M | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 2.6 M | 22nw, Lp | 2024-12-31 | 2.2 M | Monaco Asset Management | 2024-12-31 | 2 M | Ikarian Capital, Llc | 2024-12-31 | 2 M | Deep Track Capital, Lp | 2024-12-31 | 2 M | Jpmorgan Chase & Co | 2024-09-30 | 1.8 M | Blackrock Inc | 2024-12-31 | 16.1 M | Vanguard Group Inc | 2024-12-31 | 12.3 M |
Nektar Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nektar Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nektar Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Nektar Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Nektar Therapeutics Outstanding Bonds
Nektar Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Nektar Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Nektar bonds can be classified according to their maturity, which is the date when Nektar Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Pair Trading with Nektar Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nektar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nektar Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Nektar Stock
| 0.71 | OPT | Opthea | PairCorr |
| 0.6 | LTRN | Lantern Pharma | PairCorr |
| 0.58 | TMO | Thermo Fisher Scientific | PairCorr |
| 0.55 | WAT | Waters | PairCorr |
| 0.51 | VERV | Verve Therapeutics | PairCorr |
The ability to find closely correlated positions to Nektar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nektar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nektar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nektar Therapeutics to buy it.
The correlation of Nektar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nektar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nektar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nektar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Nektar Stock Analysis
When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.